Platform 3: Engineering the Immune System
This program leverages novel protocols to generate regulatory type 1 T (Tr1) cells in vitro either by activation with specific alloantigens (T-allo10) or by lentiviral vector transduction with the human IL-10 gene (LV-10) and scale up their production under cGMP conditions at Stanford’s LCGM facility. Applications include cell and organ transplantation as well as immune mediated diseases.
